A new peer-reviewed paper published in Advances in Therapeutics suggests that GLP-1 receptor agonists — the drug class that includes Ozempic and Wegovy — may offer meaningful benefits for people with cystic fibrosis, particularly those who develop cystic fibrosis-related diabetes. The findings add to a growing body of research exploring uses for GLP-1 drugs beyond their approved indications.
What the Research Found
Cystic fibrosis (CF) is a genetic disorder that causes progressive lung disease, pancreatic insufficiency, and, in many patients, a distinct form of diabetes known as cystic fibrosis-related diabetes (CFRD). According to the published review, GLP-1 receptor agonists are now being actively investigated as a potential treatment option for people with CF and CFRD.
The authors note that evidence to date has come almost entirely from case reports and case series — small-scale, individual patient accounts rather than large clinical trials. Within that limited body of evidence, these agents showed improvements in glycated hemoglobin (HbA1c), a key marker of long-term blood sugar control.
Why This Matters for the GLP-1 Community
For the millions of people already taking GLP-1 medications for type 2 diabetes or obesity, this research is a reminder that the drug class continues to be studied for a wide range of conditions. CFRD is a unique form of diabetes with different underlying mechanisms than type 1 or type 2 diabetes, making it particularly important to evaluate whether treatments developed for other populations are safe and effective for CF patients.
People with CF face complex, overlapping health challenges, and the potential for a single medication class to address blood sugar control alongside other metabolic concerns is clinically significant — if future, larger studies confirm the early signals seen in case reports.
Key takeaway: Early case-report evidence suggests GLP-1 drugs may improve blood sugar markers in people with cystic fibrosis-related diabetes, but research is still in its early stages — large clinical trials have not yet been conducted.
Important Limitations to Keep in Mind
The review is explicit that the current evidence base is narrow. Case reports and case series are considered lower-tier evidence in clinical research because they involve very small numbers of patients and lack control groups. Conclusions drawn from them are considered hypothesis-generating rather than definitive. Rigorous clinical trials will be needed before GLP-1 receptor agonists could be broadly recommended or approved specifically for CFRD.
What to Watch For Next
The publication of this review in a peer-reviewed journal signals growing academic and clinical interest in the intersection of GLP-1 therapies and cystic fibrosis. Patients, caregivers, and clinicians should watch for announcements of formal clinical trials targeting this population. Regulatory approval for this specific use would require that trial data, which does not yet exist at scale.
Frequently Asked Questions
If you or someone you care for has cystic fibrosis and questions about diabetes management or emerging treatments, speak with your prescriber or CF specialist before making any changes to your treatment plan.
- Peer-reviewed journal article, 'Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis,' Advances in Therapeutics, date not specified in source material.